DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the VIYASH SCIENTIFIC LIMITED (VIYASH) share price today?

VIYASH SCIENTIFIC LIMITED (VIYASH) is trading at ₹268.65 on the NSE, down 3.03% on the day. Source: DocStoX.

What is the PE ratio of VIYASH SCIENTIFIC LIMITED?

VIYASH SCIENTIFIC LIMITED has a price-to-earnings (PE) ratio of 66.2 in the Healthcare sector.

What is the market capitalisation of VIYASH SCIENTIFIC LIMITED?

VIYASH SCIENTIFIC LIMITED has a market capitalisation of approximately ₹11,734 crore.

VIYASH SCIENTIFIC LIMITED

VIYASH·NSE·Healthcare

₹268.65▼ -8.40 (-3.03%)

Healthcare · Pharmaceuticals

Revenue compounding 34% a year

Day₹264.60

₹277.45

52W₹178

₹29876%

Open

₹277.05

High

₹277.45

Low

₹264.60

Prev Close

₹277.05

Volume

14.70L

VWAP

₹269.36

Snapshot

Key fundamentals

Market Cap

₹11,734 Cr

P/E Ratio

66.17Expensive

P/B Ratio

4.39

EPS

₹4.06

Book Value

₹66.60

ROE

11.00%Average

ROCE

19.00%Efficient

Dividend Yield

0.18%

Debt / Equity

0.17Low

Face Value

₹2.00

52W High

₹298.00

52W Low

₹178.13

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹69

▼ 74.5%downside

Trading at ₹269 — 74% above our estimate

BearFair valueBull

₹58₹69₹79

/100

Business quality — Solid

Growth 100Profitability 28Efficiency 28Valuation 46

Plain English

Our view

Revenue compounding 34% a year
Low debt relative to equity
Expensive — trades at 66× earnings

Strengths

Low debt relative to equity
Revenue compounding 34% over 3 years
Promoters hold a controlling stake

Risks

Expensive — trades at 66× earnings
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

11% ROE fading to 12% over ~3 yrs, on ₹67 book

₹66

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹78

Analyst target

No analyst coverage

—

Blended fair value₹69

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Revenue compounding 34% over 3 years
Promoters hold a controlling stake

Bear case

Expensive — trades at 66× earnings
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

66.2Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

11.0%Average

Above 15% is considered healthy for Indian equities

ROCE

19.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.17Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹11,734 Cr

P/B

4.39

EPS

₹4.06

Div Yield

0.18%

What changed

Recent changes

Foreign investors-0.2% stake last quarter
Domestic institutions+0.6% stake last quarter
Promoters-0.10% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 66.2×

Growth

Strong

+34% rev CAGR

Profitability

Modest

11.0% ROE

Financial health

Rock solid

D/E 0.17

Momentum

N/A

No technicals

Today

Trading activity

Delivery %52.5%

Turnover₹3960.48L Cr

Trades31,507

VWAP₹269.36

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+34.0%

+20.2%

10Y

+18.9%

Profit

—

+16.7%

10Y

—

EPS

—

+1.1%

10Y

—

Profile

Pros

Company is expected to give good quarter

Watch-outs

Cons

Stock is trading at 4.17 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 6.14% over last 3 years.
Working capital days have increased from 70.3 days to 111 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters trimmed their stake by 0.10 pts; foreign investors sold 0.22 pts; domestic institutions added 0.63 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

61%

Promoter

Promoters

61.3%-0.10

Public

19.0%-0.27

FII / FPI

2.9%-0.22

DII

8.0%+0.63

Others

8.8%

Total shareholders

1,27,446-7,943 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter61.31%

FII2.94%

DII7.99%

Public18.97%

Others8.79%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions